A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

Clinical trial NCT01238692 · COMPLETED

Trial details

NCT number: NCT01238692
Sponsor: Sarit Assouline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma

Start date: 2010-11-01
Primary completion: 2016-01-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.